[{"id":"04c84023-9d31-44bc-aeb7-71f2203c82e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04877080","created_at":"2021-05-07T12:53:17.300Z","updated_at":"2024-07-02T16:35:55.885Z","phase":"Phase 1","brief_title":"CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL","source_id_and_acronym":"NCT04877080","lead_sponsor":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","biomarkers":" IL6 • IL2 • IL10","pipe":" | ","alterations":" CD19 positive • CD19 expression • CD20 negative","tags":["IL6 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD0120"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/05/2021","start_date":" 05/05/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-10"},{"id":"08b8122b-281e-4546-9d5c-29a377443acd","acronym":"GC012F-32","url":"https://clinicaltrials.gov/study/NCT04935580","created_at":"2021-06-23T18:52:53.726Z","updated_at":"2025-02-25T14:59:57.343Z","phase":"Phase 1/2","brief_title":"Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients","source_id_and_acronym":"NCT04935580 - GC012F-32","lead_sponsor":"Shanghai Changzheng Hospital","biomarkers":" IFNG • IL6 • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD0120"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/28/2021","start_date":" 06/28/2021","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2023","study_completion_date":" 07/01/2023","last_update_posted":"2022-08-03"},{"id":"5f223186-b7bf-4972-9362-db1059880282","acronym":"","url":"https://clinicaltrials.gov/study/NCT04412889","created_at":"2021-01-18T21:16:26.482Z","updated_at":"2025-02-25T14:59:09.320Z","phase":"Phase 1","brief_title":"A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM","source_id_and_acronym":"NCT04412889","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD0120"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-06-02"},{"id":"e622d4c8-0484-44ec-8cb4-52b771fbf7bb","acronym":"PGC0008","url":"https://clinicaltrials.gov/study/NCT04182581","created_at":"2021-01-18T20:23:36.726Z","updated_at":"2025-02-25T15:08:56.368Z","phase":"Phase 1","brief_title":"A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT04182581 - PGC0008","lead_sponsor":"Xijing Hospital","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD0120"],"overall_status":"Unknown status","enrollment":" Enrollment 18","initiation":"Initiation: 10/15/2019","start_date":" 10/15/2019","primary_txt":" Primary completion: 09/01/2020","primary_completion_date":" 09/01/2020","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2019-12-02"}]